Cite
HARVARD Citation
Nigam, S. et al. (2020). P081: Dual anti-HER-2 blockade with primary systemic therapy for HER-2 positive non-metastatic breast cancer can increase breast conservation rates: Benefit beyond survival. European journal of surgical oncology. 46 (6), pp. e32-. [Online].